A two-stage trial of STA-4783 in combination with weekly paclitaxel for treatment of patients with metastatic melanoma

Trial Profile

A two-stage trial of STA-4783 in combination with weekly paclitaxel for treatment of patients with metastatic melanoma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 29 Dec 2009

At a glance

  • Drugs Elesclomol; Paclitaxel
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Oct 2009 Phase II results published online first by the Journal of Clinical Oncology.
    • 13 Oct 2009 Primary endpoint 'Progression free survival duration' has been met according to results published in the Journal of Clinical Oncology.
    • 16 Sep 2008 2-year survival data were presented at ESMO in Sep 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top